Ralf Dittrich1, Laura Lotz2, Tanja Fehm3, Jan Krüssel3, Michael von Wolff4, Bettina Toth5, Hans van der Ven6, Andreas N Schüring7, Wolfgang Würfel8, Inge Hoffmann2, Matthias W Beckmann2. 1. Department of Obstetrics and Gynecology, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. Electronic address: ralf.dittrich@uk-erlangen.de. 2. Department of Obstetrics and Gynecology, Erlangen University Hospital, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany. 3. Department of Obstetrics and Gynecology, Düsseldorf University Hospital, Düsseldorf, Germany. 4. Division of Gynecologic Endocrinology and Reproductive Medicine, University Women's Hospital, Berne, Switzerland. 5. Department of Gynecologic Endocrinology and Fertility Disorders, Ruprecht-Karls University Hospital, Heidelberg, Germany. 6. Department of Obstetrics and Gynecology, Bonn University Hospital, Bonn, Germany. 7. Department of Obstetrics and Gynecology, UKM Kinderwunschzentrum, Münster University Hospital, Münster, Germany. 8. Fertility Center Munich, Munich, Germany.
Abstract
OBJECTIVE: To systematically review the reporting of MII (MII) oocyte development after xenotransplantation of human ovarian tissue. DESIGN: Systematic review in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). SETTING: Not applicable. PATIENT(S): Not applicable. INTERVENTION(S): Formation of MII oocytes after xenotransplantation of human ovarian tissue. MAIN OUTCOME MEASURE(S): Any outcome reported in Pubmed. RESULT(S): Six publications were identified that report on formation of MII oocytes after xenotransplantation of human ovarian tissue. CONCLUSION(S): Xenografting of human ovarian tissue has proved to be a useful model for examining ovarian function and follicle development in vivo. With human follicles that have matured through xenografting, the possibility of cancer transmission and relapse can also be eliminated, because cancer cells are not able to penetrate the zona pellucida. The reported studies have demonstrated that xenografted ovarian tissue from a range of species, including humans, can produce antral follicles that contain mature (MII) oocytes, and it has been shown that mice oocytes have the potential to give rise to live young. Although some ethical questions remain unresolved, xenotransplantation may be a promising method for restoring fertility. This review furthermore describes the value of xenotransplantation as a tool in reproductive biology and discusses the ethical and potential safety issues regarding ovarian tissue xenotransplantation as a means of recovering fertility.
OBJECTIVE: To systematically review the reporting of MII (MII) oocyte development after xenotransplantation of human ovarian tissue. DESIGN: Systematic review in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). SETTING: Not applicable. PATIENT(S): Not applicable. INTERVENTION(S): Formation of MII oocytes after xenotransplantation of human ovarian tissue. MAIN OUTCOME MEASURE(S): Any outcome reported in Pubmed. RESULT(S): Six publications were identified that report on formation of MII oocytes after xenotransplantation of human ovarian tissue. CONCLUSION(S): Xenografting of human ovarian tissue has proved to be a useful model for examining ovarian function and follicle development in vivo. With human follicles that have matured through xenografting, the possibility of cancer transmission and relapse can also be eliminated, because cancer cells are not able to penetrate the zona pellucida. The reported studies have demonstrated that xenografted ovarian tissue from a range of species, including humans, can produce antral follicles that contain mature (MII) oocytes, and it has been shown that mice oocytes have the potential to give rise to live young. Although some ethical questions remain unresolved, xenotransplantation may be a promising method for restoring fertility. This review furthermore describes the value of xenotransplantation as a tool in reproductive biology and discusses the ethical and potential safety issues regarding ovarian tissue xenotransplantation as a means of recovering fertility.
Authors: J-H Dalle; G Lucchini; A Balduzzi; M Ifversen; K Jahnukainen; K T Macklon; A Ahler; A Jarisch; M Ansari; E Beohou; D Bresters; S Corbacioglu; A Dalissier; C Diaz de Heredia Rubio; T Diesch; B Gibson; T Klingebiel; A Lankester; A Lawitschka; R Moffat; C Peters; C Poirot; N Saenger; P Sedlacek; E Trigoso; K Vettenranta; J Wachowiak; A Willasch; M von Wolff; I Yaniv; A Yesilipek; P Bader Journal: Bone Marrow Transplant Date: 2017-03-13 Impact factor: 5.483
Authors: Karin Hammarberg; Maggie Kirkman; Catharyn Stern; Robert I McLachlan; Debra Gook; Luk Rombauts; Beverley Vollenhoven; Jane R W Fisher Journal: BMC Health Serv Res Date: 2017-05-10 Impact factor: 2.655
Authors: Lotte Eijkenboom; Callista Mulder; Bert van der Reijden; Norah van Mello; Julia van Leersum; Thessa Koorenhof-Scheele; Didi Braat; Catharina Beerendonk; Ronald Peek Journal: J Assist Reprod Genet Date: 2021-03-16 Impact factor: 3.412